Coherus BioSciences (NASDAQ:CHRS – Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share for the quarter.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to analyst estimates of $57.08 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Coherus BioSciences Trading Down 1.9 %
Shares of NASDAQ CHRS opened at $0.74 on Thursday. Coherus BioSciences has a twelve month low of $0.71 and a twelve month high of $3.73. The company has a market capitalization of $84.43 million, a price-to-earnings ratio of -0.96 and a beta of 0.65. The firm has a 50-day moving average of $1.10 and a two-hundred day moving average of $1.52.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Coherus BioSciences
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Further Reading
- Five stocks we like better than Coherus BioSciences
- Why Are Stock Sectors Important to Successful Investing?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Are Penny Stocks a Good Fit for Your Portfolio?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.